RedHill Biopharma reported $6.53M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Cara Therapeutics USD 25.33M 6.21M Mar/2026
Clal Biotechnology ILS 14.69M 1.95M Dec/2023
Compugen USD 137.28M 10.74M Mar/2026
Cronos Group USD 912.03M 15.85M Jun/2026
RedHill Biopharma USD 6.53M 6.03M Dec/2025